Hims & Hers Health Target of Unusually Large Options Trading (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the recipient of unusually large options trading on Wednesday. Investors purchased 322,282 call options on the stock. This represents an increase of 128% compared to the typical volume of 141,619 call options.

Insider Activity

In other news, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the sale, the insider directly owned 2,126 shares of the company’s stock, valued at $78,045.46. This represents a 79.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the transaction, the insider directly owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 80,463 shares of company stock valued at $2,846,696. 13.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in Hims & Hers Health during the fourth quarter worth $80,000. SHP Wealth Management purchased a new stake in Hims & Hers Health in the 4th quarter valued at about $106,000. Caitong International Asset Management Co. Ltd raised its holdings in Hims & Hers Health by 413.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 17,228 shares of the company’s stock valued at $559,000 after buying an additional 13,873 shares during the period. MidFirst Bank acquired a new position in Hims & Hers Health in the fourth quarter valued at about $146,000. Finally, Pacer Advisors Inc. lifted its holdings in shares of Hims & Hers Health by 83.6% in the 4th quarter. Pacer Advisors Inc. now owns 50,054 shares of the company’s stock worth $1,625,000 after acquiring an additional 22,794 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Up 10.3%

Shares of NYSE HIMS opened at $25.89 on Thursday. The stock has a market cap of $5.90 billion, a PE ratio of 50.76, a P/E/G ratio of 4.55 and a beta of 2.55. The company has a 50-day moving average of $24.18 and a 200 day moving average of $37.66. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter last year, the firm earned $0.11 earnings per share. The business’s revenue for the quarter was up 28.4% on a year-over-year basis. As a group, sell-side analysts predict that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to buy up to 3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

Several brokerages have weighed in on HIMS. TD Cowen cut their price target on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a research report on Tuesday, February 24th. Truist Financial reiterated a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Monday. Leerink Partners dropped their target price on Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating on the stock in a research report on Tuesday, February 24th. Finally, Morgan Stanley dropped their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $30.75.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Landmark Novo Nordisk partnership — the deal replaces compounded GLP‑1 sales with distribution of branded Wegovy/Ozempic (including new pill forms), materially reducing legal risk and legitimizing HIMS’ platform; analysts and market commentary see this as transformational for revenue and margins. Read More. Read More.
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Barclays, Needham, Deutsche Bank and others) have raised ratings/targets after the Novo news, supporting upside and prompting fresh buy interest. Read More. Read More.
• Positive Sentiment: Large call‑option activity — unusually heavy call buying (322k calls, ~128% above normal) signals speculative and directional bullish positioning that can amplify intraday moves and volatility. Read More.
• Neutral Sentiment: Strong 2025 operating results provide context — HIMS reported $2.35B revenue (+59% YoY), solid EBITDA and cash flow, and 2.5M+ subscribers with improving ARPU/cross‑sell metrics, which support a longer‑term bull case but leave execution risk. Read More.
• Neutral Sentiment: Corporate hire and platform expansion — appointment of a new Chief Communications Officer and product/platform expansions are governance/brand positives but are longer‑dated catalysts. Read More.
• Neutral Sentiment: Mixed brokerage consensus — while a number of firms upgraded, the street average rating remains around “Hold,” so fresh positive headlines may be needed to sustain multiple expansion. Read More.
• Negative Sentiment: Some institutional selling noted — at least one asset manager trimmed/exit positions despite the deal; this could add supply and headwinds if other holders follow. Read More.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.